Evidence map›Paper›PMID 26620842›Full record

ArticleVaccine2016

Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.

Hong Xin

Abstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Vaccines against candidiasis: Status, challenges and emerging opportunity.Frontiers in cellular and infection microbiology · 2022
    Review
  5. Review
  6. Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020
    Review
  7. Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hong XinDepartment of Pediatrics, Louisiana State University Health Sciences Center and Research Institute for Children, Children's Hospital, New Orleans, LA 70118, United States. Electronic address: hxin@chnola-research.org.
Louisiana State University Health Sciences Center New Orleans · US

Funding

Design of a mimotope-peptide based double epitope vaccine against candidiasisR21AI113515 · NIAID · LSU HEALTH SCIENCES CENTER · PI XIN, HONG · 2015 to 2016
$391k
Synthetic glycopeptide vaccines that enhance resistance to candidiasisR03AI107536 · NIAID · CHILDREN'S HOSPITAL (NEW ORLEANS) · PI XIN, HONG · 2013 to 2014
$164k
NIAID NIH HHS R03 AI107536NIAID NIH HHS R03 AI107536-02NIAID NIH HHS R21 AI113515
6 · The paper itself

Abstract

We previously report that peptide-pulsed dendritic cell (DC) vaccination, which targeting two peptides (Fba and Met6) expressed on the cell surface of Candida albicans, can induce high degree of protection against disseminated candidiasis in immunocompetent mice. Passive transfer of immune sera from the peptide immunized mice or peptide-related monoclonal antibodies demonstrated that protection was medicated by peptide-specific antibodies. In this study the efficacy of active and passive immunization against disseminated candidiasis was tested in mice with cyclophosphamide-induced neutropenia. Peptide-DC vaccines were given to mice prior to induction of neutropenia. We show active immunization with either Fba or Met6 peptide-DC vaccine significantly improved the survival and reduced the fungal burden of disseminated candidiasis in those immunocompromised mice. Importantly, we show that administration of two protective monoclonal antibodies also protect neutropenic mice against the disease, implying possibility of developing a successful passive immunotherapy strategy to treat the disease and protect against disseminated candidiasis. The results of this study are crucial as they address the fundamental questions as to whether the synthetic peptide vaccine induced immunity protects the host during a neutropenic episode. We anticipate that this peptide-vaccine study will serve as the foundation of future investigations into new peptide vaccines comprised of cell surface peptides from other medically important Candida species, as well as other fungi.

Indexed as

AnimalsAntibodies, FungalCandida albicansCandidiasisColony Count, MicrobialDisease Models, AnimalFemaleFungal VaccinesImmunization, PassiveMice, Inbred BALB CNeutropeniaSurvival AnalysisTreatment OutcomeVaccinationVaccines, SubunitAntibodies, FungalFungal VaccinesVaccines, SubunitAntibody protectionCandidiasisNeutropeniaPeptide vaccine

Identifiers

PMID26620842
PMCPMC4698214
OpenAlexW2174244465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.